BRPI0918211A2 - métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf - Google Patents

métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf

Info

Publication number
BRPI0918211A2
BRPI0918211A2 BRPI0918211A BRPI0918211A BRPI0918211A2 BR PI0918211 A2 BRPI0918211 A2 BR PI0918211A2 BR PI0918211 A BRPI0918211 A BR PI0918211A BR PI0918211 A BRPI0918211 A BR PI0918211A BR PI0918211 A2 BRPI0918211 A2 BR PI0918211A2
Authority
BR
Brazil
Prior art keywords
methods
patient
expression level
level detection
detection kit
Prior art date
Application number
BRPI0918211A
Other languages
English (en)
Inventor
Paul J Fielder
Qun Jenny Wu
Yibing Yan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0918211A2 publication Critical patent/BRPI0918211A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
BRPI0918211A 2008-12-23 2009-12-22 métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf BRPI0918211A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14039208P 2008-12-23 2008-12-23
PCT/US2009/069254 WO2010075420A1 (en) 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
BRPI0918211A2 true BRPI0918211A2 (pt) 2015-12-08

Family

ID=41664930

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918211A BRPI0918211A2 (pt) 2008-12-23 2009-12-22 métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf

Country Status (13)

Country Link
US (4) US20100216115A1 (pt)
EP (1) EP2382472B1 (pt)
JP (1) JP5416221B2 (pt)
KR (3) KR20140020368A (pt)
CN (1) CN102265157B (pt)
AU (2) AU2009329994B2 (pt)
BR (1) BRPI0918211A2 (pt)
CA (1) CA2746120A1 (pt)
ES (1) ES2541925T3 (pt)
IL (2) IL213410A (pt)
MX (2) MX2011006875A (pt)
SG (3) SG10201604988YA (pt)
WO (1) WO2010075420A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311981B1 (en) 2007-05-01 2014-09-17 The Regents of The University of California Methods for diagnosing ischemia
WO2012009547A2 (en) 2010-07-14 2012-01-19 The Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
WO2012009567A2 (en) 2010-07-15 2012-01-19 The Regents Of The University Of California Biomarkers for diagnosis of stroke and its causes
EP2848940A1 (en) * 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR20130091746A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
MX2013000676A (es) * 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer.
MX343801B (es) * 2010-07-19 2016-11-23 F Hoffmann-La Roche Ag * Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
EP2311865A1 (en) * 2010-11-19 2011-04-20 F. Hoffmann-La Roche AG Placental Growth Factor in Cancer Disease
WO2012121978A2 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Biomarkers for the diagnosis of lacunar stroke
CA2840687C (en) 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
US9410204B2 (en) 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
AU2013207778B2 (en) 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists
CN103207274B (zh) * 2013-04-28 2015-02-25 成都中医药大学 一种胎儿7号染色体异常疾病的筛查试剂盒
CN103235142B (zh) * 2013-04-28 2015-04-15 成都中医药大学 一种孕妇初次妊娠筛查试剂盒
CA2922398C (en) * 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
CA2930326C (en) 2013-12-06 2022-09-06 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
WO2016041614A1 (en) * 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
AU2017258510A1 (en) 2016-04-29 2018-10-11 Dana-Farber Cancer Institute, Inc. HCK as a therapeutic target in MYD88 mutated diseases
CN107037210A (zh) * 2017-04-05 2017-08-11 北京蛋白质组研究中心 Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用
US20230184770A1 (en) * 2020-04-22 2023-06-15 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Exosome Analysis And Brain Tumors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2173873T5 (es) 1992-10-28 2007-03-01 Genentech, Inc. Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer.
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US20020081597A1 (en) 2000-03-31 2002-06-27 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
SI1638941T1 (sl) 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1753442A2 (en) * 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CN101184776B (zh) * 2005-03-24 2013-04-24 斯路姆基因公司 新型抗胎盘生长因子抗体
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
KR20080106946A (ko) * 2006-03-29 2008-12-09 제넨테크, 인크. 종양의 진단 및 치료
JP4699311B2 (ja) * 2006-08-22 2011-06-08 太陽社電気株式会社 チップ抵抗器

Also Published As

Publication number Publication date
IL236786A (en) 2017-05-29
AU2009329994B2 (en) 2014-04-03
US20130022596A1 (en) 2013-01-24
JP2012513592A (ja) 2012-06-14
JP5416221B2 (ja) 2014-02-12
AU2014203615A1 (en) 2014-07-17
SG172355A1 (en) 2011-07-28
SG10201604988YA (en) 2016-07-28
ES2541925T3 (es) 2015-07-28
KR20160021308A (ko) 2016-02-24
EP2382472B1 (en) 2015-05-06
KR101596539B1 (ko) 2016-02-22
KR20140020368A (ko) 2014-02-18
EP2382472A1 (en) 2011-11-02
CN102265157A (zh) 2011-11-30
IL213410A0 (en) 2011-07-31
MX2011006875A (es) 2011-07-20
AU2009329994A1 (en) 2011-07-07
MX2018011832A (es) 2020-09-14
WO2010075420A1 (en) 2010-07-01
US20130224194A1 (en) 2013-08-29
IL213410A (en) 2015-02-26
US20130224193A1 (en) 2013-08-29
CN102265157B (zh) 2014-11-26
CA2746120A1 (en) 2010-07-01
US20100216115A1 (en) 2010-08-26
KR20110106899A (ko) 2011-09-29
SG187385A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
BRPI0918211A2 (pt) métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
BRPI0917250A2 (pt) sistema para detecção de tecido em um paciente, sistema para detectar característica de tecido em um paciente
BRPI0914801A2 (pt) método para detectar o grupo sanguíneo abo/rh/mn humano, e, kit
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
BRPI0912729A2 (pt) válvula de controle do sangue por compressão radial
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI0907021A2 (pt) Metodologia para interpretação e análise das distribuições de rmn
DK2196922T3 (da) Fremgangsmåde til at opsamle analysedata for menneskelige oplevelser
LTPA2016041I1 (lt) Gydymo būdai panaudojant vaistus - amoniako gaudykles
BRPI0906834A2 (pt) Sistema de monitoramento de fibrilação atrial
BRPI1009004A2 (pt) método para integrar diagnóstico e tratamento para tecidos internos, e, sistema para integrar diagnóstico e tratamento para tecidos internos
BRPI0921919A2 (pt) dispositivos médicos, aparelhos, sistemas e métodos
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
BRPI0817022A2 (pt) Sistema de estimalução vestibular, e, método para fornecer estimulação vestibular para um usuário
DK2205817T3 (da) Forankrede slamretursystemer uden stigrør
BRPI0913227A2 (pt) método, e objeto
BRPI1007996A2 (pt) fluido de tratamento, e, método
BRPI0913752A2 (pt) método, dispositivo, e, estrutura
DK3567363T3 (da) Prøvningsindretninger, -fremgangsmåder og reagenser
BRPI0912380A2 (pt) válvula para controle de sangue rotacionalmente ativada
BRPI0911666A2 (pt) sistema para cirurgia oftalmológica refrativa.
BRPI0906440A2 (pt) Dispositivo de controle de acesso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2611 DE 19-01-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.